Growth Metrics

Solid Biosciences (SLDB) Change in Accured Expenses (2017 - 2026)

Quarterly results put Change in Accured Expenses at -$473000.0 for Q1 2026, down 72.0% from a year ago — trailing twelve months through Mar 2026 was $3.9 million (down 9.96% YoY), and the annual figure for FY2025 was $4.0 million, down 15.02%.

Solid Biosciences has reported Change in Accured Expenses over the past 10 years, most recently at -$473000.0 for Q1 2026.

  • Change in Accured Expenses reached -$473000.0 in Q1 2026 per SLDB's latest filing, down from $152000.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $8.7 million in Q2 2022 and bottomed at -$5.0 million in Q3 2022.
  • Median Change in Accured Expenses over the past 5 years was $152000.0 (2025), compared with a mean of $424000.0.
  • Peak annual rise in Change in Accured Expenses hit 1515.01% in 2022, while the deepest fall reached 1544.37% in 2022.
  • Over 5 years, Change in Accured Expenses stood at $2.6 million in 2022, then plummeted by 164.03% to -$1.6 million in 2023, then soared by 198.72% to $1.6 million in 2024, then plummeted by 90.64% to $152000.0 in 2025, then plummeted by 411.18% to -$473000.0 in 2026.
  • Business Quant data shows Change in Accured Expenses for SLDB at -$473000.0 in Q1 2026, $152000.0 in Q4 2025, and $2.2 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Accured Expenses (Qtr)
1 Quantum Biopharma 1,384,976.65 Bn 1,384,976.64 Bn - -
2 Alterity Therapeutics 777,208.84 Bn 777,208.81 Bn - -
3 Legend Biotech 2,801.00 Bn 2,800.10 Bn 242.10 Mn -
4 Nanobiotix 2,226.01 Bn 2,225.95 Bn - -
5 Akari Therapeutics 605.66 Bn 605.66 Bn - 931,000.00
6 Vertex Pharmaceuticals 110.17 Bn 102.92 Bn 2.59 Bn 70.50 Mn
7 Regeneron Pharmaceuticals 66.86 Bn 58.11 Bn 3.31 Bn 107.70 Mn
8 Evaxion A 65.12 Bn 65.10 Bn - -
9 Alnylam Pharmaceuticals 39.94 Bn 36.94 Bn 959.66 Mn -176.03 Mn
10 Solid Biosciences 713.77 Mn 333.09 Mn - -473,000.00

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -473,000.00
Mar 31, 2026 -473,000.00
Dec 31, 2025 152,000.00
Dec 31, 2025 152,000.00
Sep 30, 2025 2.20 Mn
Sep 30, 2025 2.20 Mn
Jun 30, 2025 1.97 Mn
Jun 30, 2025 1.97 Mn
Mar 31, 2025 -275,000.00
Mar 31, 2025 -275,000.00
Dec 31, 2024 1.62 Mn
Dec 31, 2024 1.62 Mn
Sep 30, 2024 3.31 Mn
Sep 30, 2024 3.31 Mn
Jun 30, 2024 -380,000.00
Jun 30, 2024 -380,000.00
Mar 31, 2024 213,000.00
Mar 31, 2024 213,000.00
Dec 31, 2023 -1.65 Mn
Dec 31, 2023 -1.65 Mn
Sep 30, 2023 906,000.00
Sep 30, 2023 906,000.00
Jun 30, 2023 -1.32 Mn
Jun 30, 2023 -1.32 Mn
Mar 31, 2023 -4.91 Mn
Mar 31, 2023 -4.91 Mn
Dec 31, 2022 2.57 Mn
Dec 31, 2022 2.57 Mn
Sep 30, 2022 -4.97 Mn
Sep 30, 2022 -4.97 Mn
Jun 30, 2022 8.67 Mn
Jun 30, 2022 8.67 Mn
Mar 31, 2022 -445,000.00
Mar 31, 2022 -445,000.00
Dec 31, 2021 2.58 Mn
Dec 31, 2021 2.58 Mn
Sep 30, 2021 -302,000.00
Sep 30, 2021 -302,000.00
Jun 30, 2021 -613,000.00
Jun 30, 2021 -613,000.00
Mar 31, 2021 -3.92 Mn
Mar 31, 2021 -3.92 Mn
Dec 31, 2020 887,000.00
Dec 31, 2020 887,000.00
Sep 30, 2020 -226,000.00
Sep 30, 2020 -226,000.00
Jun 30, 2020 -643,000.00
Jun 30, 2020 -643,000.00
Mar 31, 2020 -1.18 Mn
Mar 31, 2020 -1.18 Mn
Dec 31, 2019 -2.92 Mn
Dec 31, 2019 -2.92 Mn
Sep 30, 2019 5.10 Mn
Sep 30, 2019 5.10 Mn
Jun 30, 2019 -1.44 Mn
Jun 30, 2019 -1.44 Mn
Mar 31, 2019 -1.25 Mn
Mar 31, 2019 -1.25 Mn
Dec 31, 2018 2.70 Mn
Dec 31, 2018 2.70 Mn
Sep 30, 2018 990,000.00
Sep 30, 2018 990,000.00
Jun 30, 2018 546,000.00
Jun 30, 2018 546,000.00
Mar 31, 2018 -1.35 Mn
Mar 31, 2018 -1.35 Mn
Dec 31, 2017 991,000.00
Dec 31, 2017 991,000.00
Sep 30, 2017 -22,000.00
Sep 30, 2017 -22,000.00
Jun 30, 2017 1.79 Mn
Jun 30, 2017 1.79 Mn
Mar 31, 2017 -725,000.00
Mar 31, 2017 -725,000.00